<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01416428</url>
  </required_header>
  <id_info>
    <org_study_id>2011-001</org_study_id>
    <nct_id>NCT01416428</nct_id>
  </id_info>
  <brief_title>Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies</brief_title>
  <official_title>Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and
      safety of oprozomib in patients with hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 12, 2019</completion_date>
  <primary_completion_date type="Actual">August 12, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the MTD (Phase 1) and ORR (Phase 2).</measure>
    <time_frame>6 weeks to 18 months</time_frame>
    <description>Phase 1- Determine Maximum Tolerated Dose (MTD) with 3 + 3 Dose Escalation Cohorts in patients hematologic malignancies.
Phase 2- The Phase 2 portion of this trial will enroll patients with Multiple Myeloma (MM) and Waldenstrom Macroglobulinemia (WM) into separate arms to assess activity of oprozomib in these patient groups. The purpose of the Phase 2 portion of the study is to estimate the best ORR (for each group separately).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the duration of response (DOR)</measure>
    <time_frame>64 months</time_frame>
    <description>Duration of Response is defined as the time from first evidence of partial response (PR) or better to confirmation of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the clinical benefit response (CBR)</measure>
    <time_frame>64 months</time_frame>
    <description>CBR is defined as Overall Response Rate (ORR) plus Minimal Response (MR) of oprozomib in patients with multiple myeloma (MM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the major response for Waldenström macroglobulinemia (WM)</measure>
    <time_frame>64 months</time_frame>
    <description>Major response for WM subjects is defined as Complete Response (CR) plus Very Good Partial Response (VGPR) plus Partial Response (PR). Major response to be equal or greater than (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate progression-free survival (PFS) for multiple myeloma (MM) subjects</measure>
    <time_frame>64 months</time_frame>
    <description>Progression-Free Survival is defined as the time from the start of treatment to disease progression or death (due to any cause), whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PFS for Waldenström macroglobulinemia (WM) subjects</measure>
    <time_frame>64 months</time_frame>
    <description>Progression-Free Survival is defined as the time from the start of treatment to disease progression or death (due to any cause), whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - maximum plasma concentration (Cmax)</measure>
    <time_frame>55 months</time_frame>
    <description>PK analyses to be performed on oprozomib and its metabolite(s) concentrations in order to estimate the maximum observed drug concentration (Cmax) value after oral administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - time of maximum plasma concentration (tmax)</measure>
    <time_frame>55 months</time_frame>
    <description>PK analyses to be performed on oprozomib and its metabolite(s) concentrations in order to estimate the time to reach Cmax (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - plasma concentration-time curve (AUC)</measure>
    <time_frame>55 months</time_frame>
    <description>PK analyses to be performed on oprozomib and its metabolite(s) concentrations in order to estimate the area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess renal elimination of oprozomib and its metabolites (Phase 1b only)</measure>
    <time_frame>55 months</time_frame>
    <description>Urine will be collected over 24 hours to assess renal elimination of oprozomib and its metabolites following dosing on Day 1 of Cycle 1 for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in hematology laboratory results</measure>
    <time_frame>64 months</time_frame>
    <description>Assess the change from baseline in hematology panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in serum chemistry results</measure>
    <time_frame>64 months</time_frame>
    <description>Assess the change from baseline in serum chemistry panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in vital signs</measure>
    <time_frame>64 months</time_frame>
    <description>Assess the change from baseline in vital signs including blood pressure, pulse, and temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in weight</measure>
    <time_frame>64 months</time_frame>
    <description>Assess the change from baseline in weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety of oprozomib in Phase 2</measure>
    <time_frame>Until 30 days after the end of study (64 months)</time_frame>
    <description>Safety to be defined by incidence, nature, severity, and relatedness of adverse events (AEs), including all serious adverse events (SAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect on transfusion/ red blood cell (RBC) growth factor requirements (Phase 2 only) for WM only</measure>
    <time_frame>64 months</time_frame>
    <description>Change from Baseline (prior 1 month) transfusion/RBC growth factor requirement in frequency and volume in WM (Phase 2 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect on plasmapheresis requirements (Phase 2 only) for WM only</measure>
    <time_frame>64 months</time_frame>
    <description>Change from Baseline (prior 1 month) plasmapheresis requirement in frequency and volume in WM (Phase 2 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect on lymphoplasmacytic cells in the bone marrow (Phase 2 only) for WM only</measure>
    <time_frame>64 months</time_frame>
    <description>Change from Baseline in percent of lymphoplasmacytic cells in the bone marrow in WM (Phase 2 only)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>QDx2 Dosing Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QDx2 is defined as patients receiving Oprozomib Tablets once daily on Days 1, 2, 8, and 9 of the 14-day cycle.
The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QDx5 Dosing Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QDx5 is defined as patients receiving Oprozomib Tablets once daily on Days 1 to 5 of the 14-day cycle.
The schedule will be evaluated in Phase 1 for MTD in patients with hematologic malignancies, and will also be evaluated in Phase 2 for ORR in patients with MM and WM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oprozomib</intervention_name>
    <description>Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.</description>
    <arm_group_label>QDx2 Dosing Schedule</arm_group_label>
    <arm_group_label>QDx5 Dosing Schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        Phase 1b

          -  Histologically confirmed diagnosis of a hematologic malignancy, excluding patients
             with acute leukemia or MDS.

          -  Relapsed after standard therapy for their malignancy and considered to be an
             appropriate candidate for a Phase 1 clinical study by their treating physician.

        Phase 2

          -  Multiple myeloma with measurable disease

          -  Waldenström macroglobulinemia with symptomatic relapse

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

        Ethical/Other

          -  Patients must sign a written informed consent form in accordance with federal, local,
             and institutional guidelines.

          -  Female patients of childbearing potential must have a negative serum or urine
             pregnancy test and agree to use effective contraception. Male patients must use an
             effective barrier method of contraception.

        EXCLUSION CRITERIA:

          -  Chemotherapy with approved or investigational anticancer therapeutics, including
             steroid therapy intended to treat underlying malignancy, within 3 weeks prior to first
             dose or 6 weeks for antibody therapy.

          -  Radiation therapy within 3 weeks prior to first dose. Radioimmunotherapy within 8
             weeks prior to first dose. Localized radiation therapy within 1 week prior to first
             dose.

          -  Immunotherapy within 3 weeks prior to first dose (except for antibody therapy, where 6
             weeks is required).

          -  Prior stem cell transplant (SCT) therapy (autologous SCT within the prior 8 weeks;
             allogeneic SCT within the prior 16 weeks). Patients with prior allogeneic SCT should
             not have evidence of moderate-to-severe graft-vs-host disease (GvHD; as defined in
             Filipovich 2005).

          -  Evidence of central nervous system (CNS) lymphoma.

          -  Prior treatment with carfilzomib unless in the phase 2.

          -  Major surgery within 3 weeks prior to first dose.

          -  Symptomatic Congestive heart failure, ischemia, conduction abnormalities, or
             myocardial infarction within 6 months.

          -  Acute active infection requiring systemic antibiotics, antivirals, or antifungals.

          -  Known or suspected human immunodeficiency virus (HIV) infection or patients who are
             HIV seropositive.

          -  Active hepatitis A, B, or C infection.

          -  Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the
             first dose.

          -  Patients with pleural effusions requiring routine thoracentesis or ascites requiring
             routine paracentesis.

          -  History of previous clinically significant GI bleed in the last 6 months prior to
             first dose.

          -  Female patients who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Care</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Division of Oncology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology of Northern New Jersey</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute / Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Basin Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2011</study_first_posted>
  <disposition_first_submitted>March 19, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>March 19, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 23, 2020</disposition_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>waldenstrom macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

